MedWatch

Leo Pharma eczema drug makes Express Scripts preferred product list

Express Scripts, the biggest pharmacy benefit manager (PBM) in the US, has made Leo Pharma’s Adbry one of its preferred products, putting the Danish atopic eczema treatment at the same level as its blockbuster competition, Sanofi’s Dupixent.

Leo Pharma's Adbry is now listed as one of the preferred products of Express Scripts, the biggest PDM in the US.

Leo Pharma’s atopic eczema drug, Adbry (tralokinumab), is now on the list of preferred drugs at Express Scripts, which is the biggest pharmacy benefit manager (PBM) in the US with 22 million customers across 50 states.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs